Stem Cell Therapy Market Trends and Growth Forecast to 2030

NEW YORK - March 19, 2025 - PRLog -- According to the latest market research study published by P&S Intelligence, the global stem cell therapy market, valued at USD 306.1 million in 2023, is poised for significant growth, with projections to reach USD 910.8 million by 2030.

This rapid expansion, at a CAGR of 16.9% from 2024 to 2030, is driven by the rising prevalence of conditions such as traumatic injuries, orthopedic diseases, neurological disorders, and autoimmune diseases like multiple sclerosis, lupus, and Parkinson's disease. The growing awareness and advancements in stem cell research are further contributing to market growth, with increasing demand for stem cell banking and personalized treatments. For example, in 2022, the California Institute for Regenerative Medicine invested USD 8 million to enhance stem cell therapies.

Key Insights

Segmentation Analysis:

• The market is categorized by therapy type, with allogeneic stem cell therapy holding the largest share of 60% in 2023. This category is expected to grow at a CAGR of 17.0% during the forecast period, driven by numerous clinical trials and its benefits like grafts that do not carry tumor cells.
• Autologous stem cell therapy is projected to experience significant growth due to the lower risk of graft rejection and its application in treating conditions like multiple sclerosis through hematopoietic stem cell transplants.

Regional and Geographical Trends:

• North America continues to dominate the stem cell therapy market, primarily due to advanced healthcare infrastructure, significant investment in regenerative medicine, and government-backed initiatives.
• Europe is also a key player, with growing clinical trials and increasing healthcare budgets allocated for stem cell research.

Browse detailed report analysis on "Stem Cell Therapy Market Growth and Forecast Report, 2030 (https://www.psmarketresearch.com/market-analysis/stem-cel...)"

Technological Advancements:

• Advances in cell therapy technologies, such as the development of omidubicel for hematopoietic stem cell transplantation, are enhancing treatment effectiveness, particularly in blood-related diseases.
• Innovations in stem cell banking, particularly with adipose-derived stem cells, are improving the collection and application processes, allowing for minimally invasive methods and more efficient treatments.

Competitive Dynamics and Emerging Opportunities:

• Major companies, including InGeneron Inc. and American CryoStem, are leading clinical trials for stem cell therapies, with studies focusing on conditions like post-concussion syndrome and osteoarthritis.
• New market players are emerging with promising treatments, creating opportunities for collaboration, investment, and technological partnerships. For instance, Jasper Therapeutics' clinical trials demonstrate the potential to augment current bone marrow transplant procedures, showcasing the evolving competitive landscape.